AXSM vs JAZZ
AXSM: A biopharmaceutical company developing and commercializing innovative therapies for central nervous system disorders. JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for patients with complex sleep disorders and challenging oncology conditions.
Side-by-side fundamentals
| Metric | AXSM | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $170.08 | $222.45 | |
| Market cap | $8.9B | $14.4B | |
| P/E as of 2026-10-08 | n/a | 15.21 | |
| Net margin FY2025, SEC XBRL | -28.7% | -8.3% | JAZZ higher |
| Operating margin FY2025, SEC XBRL | -26.1% | -10.1% | JAZZ higher |
| ROE FY2025, SEC XBRL | -207.5% | -8.2% | JAZZ higher |
| ROA FY2025, SEC XBRL | -26.6% | -3.1% | JAZZ higher |
| Debt / equity as of 2026-09-03 | 2.43 | 0.91 | JAZZ lower |
| Revenue growth (YoY) as of 2026-09-03 | +56.9% | +12.6% | AXSM higher |
| Revenue CAGR (3y) SEC XBRL | +133.7% | +5.3% | AXSM higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.67 | 0.75 | |
| 1-year return as of 2026-10-08 close | +43.3% | +61.5% | JAZZ higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.